Immune checkpoint inhibitors have transformed cancer treatment by releasing molecular “brakes” that normally restrain T cells. Drugs targeting pathways such as PD-1, PD-L1 and CTLA-4 can therefore enhance the immune system’s ability to recognize and destroy tumor cells. However, the same amplified immune response can sometimes damage healthy tissues. When immune cells attack the joints, patients may develop immune checkpoint inhibitor-mediated inflammatory arthritis, a painful condition that can include swelling, stiffness and reduced mobility.

The complication is not necessarily limited to the period when patients are receiving treatment. According to the researchers, approximately 20% to 50% of affected patients experience arthritis more than once, while some continue to have symptoms for months or years after immunotherapy ends. Recurrent flares can be particularly disruptive, and clinical observations indicate that they are often more intense than the initial episode. Until now, it has remained unclear whether each flare represents a new inflammatory event or the reactivation of immune cells established during the first attack.

To investigate that question, researchers analyzed joint fluid collected from six patients during an initial arthritis flare and a subsequent recurrence. Joint fluid provides a direct view of the immune environment inside inflamed tissue, allowing scientists to examine the cells and signaling molecules active at the site of disease. Using immune profiling and molecular analyses, the team found two prominent immune cell populations in both episodes: inflammatory CD8 T cells and a specialized subset of CD4 T cells that simultaneously expressed PD-1 and CXCL13.

CD8 T cells are typically associated with the direct destruction of infected or abnormal cells, but in inflammatory arthritis they can also contribute to tissue damage by releasing cytokines and other immune mediators. PD-1 and CXCL13 co-expressing CD4 T cells represent a more specialized population involved in organizing immune reactions. PD-1 is a receptor associated with T-cell activation and regulation, while CXCL13 is a chemokine that helps attract and position immune cells within organized inflammatory niches. Their persistence across separate flares suggests that the joint may retain, or repeatedly recruit, a disease-associated immune network.

The researchers also found that these immune populations appeared to become more aggressive during recurrent disease. Cells present in the second flare produced higher levels of inflammatory signaling molecules, indicating that they were not merely surviving in the tissue but returning in a more activated state. This pattern resembles immunological memory, in which previously stimulated immune cells respond more rapidly and forcefully when they encounter a familiar signal. In this case, the response is directed toward joint-associated inflammation rather than a tumor or infectious pathogen.

An unexpected finding involved regulatory T cells, or Tregs. These cells ordinarily help prevent excessive immune activation and maintain tolerance to the body’s own tissues. During recurrent arthritis flares, however, Tregs also produced inflammatory molecules. The observation raises the possibility that regulatory cells may lose some of their protective function or become functionally altered within the highly inflammatory environment created by checkpoint inhibitor therapy. If confirmed in larger studies, this change could help explain why the body’s normal mechanisms for limiting joint inflammation fail during repeated episodes.

The study further revealed extensive communication networks among immune cells in the affected joints. These networks were characterized by signaling molecules that coordinate cell recruitment, activation and persistence. During the second flare, the connections became more pronounced, suggesting that recurrent arthritis is driven by a coordinated inflammatory ecosystem rather than by a small number of isolated cell types. Such molecular interactions may amplify inflammation over time and could provide multiple points for therapeutic intervention.

The findings may eventually help clinicians identify patients at high risk of recurrent arthritis before severe flares develop. The presence or activity of inflammatory CD8 T cells and PD-1-positive, CXCL13-producing CD4 T cells could potentially serve as biomarkers, although the results must be validated in larger patient groups. Researchers also hope to develop treatments that selectively interrupt the pathways responsible for joint inflammation without weakening the anti-cancer immune response. That balance is crucial: broadly suppressing immunity could reduce arthritis but might also compromise the ability of checkpoint inhibitors to control cancer.

Roza I. Nurieva, Ph.D., who co-led the study with Synat Keam, Ph.D., Yuanteng Jeff Li, M.D., and Sang Taek Kim, M.D., Ph.D., said that the persistence of anti-tumor immunity may have an unintended counterpart in recurring inflammatory disease. By defining the cells and molecular signals associated with repeated arthritis flares, the researchers have provided a framework for understanding this challenging side effect as an immune-memory process. Future work will determine whether these cellular signatures can predict recurrence and whether targeted therapies can protect patients’ joints while preserving the life-extending benefits of cancer immunotherapy.

Subject of Research: Immune checkpoint inhibitor-mediated recurrent inflammatory arthritis and its immune-cell mechanisms

Article Title: Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis

News Publication Date: August 11, 2026

Web References: The University of Texas MD Anderson Cancer Center; Cancer Immunology Research; https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066.CIR-25-1639/787231/Immune-hallmarks-of-recurrent-immune-checkpoint

References: DOI: 10.1158/2326-6066.CIR-25-1639

Image Credits: The University of Texas MD Anderson Cancer Center

Keywords: inflammatory arthritis, immune checkpoint inhibitors, cancer immunotherapy, immunological memory, CD8 T cells, CD4 T cells, PD-1, CXCL13, regulatory T cells, biomarkers, cancer research, immune-related adverse events

Recent groundbreaking studies have begun to unearth a pivotal yet underexplored player in this delicate immunological balance—the tissue-resident microbiome. Particularly, the microbiota inhabiting mucosal barriers such as the gut, lungs, and skin have emerged as influential regulators of immune homeostasis and potentially, immune-related toxicity profiles in patients undergoing ICI therapy. The gastrointestinal tract microbiome, by virtue of its sheer density and reciprocal crosstalk with the host immune system, is garnering intense scrutiny for its contributory role in the most prevalent irAE: ICI-induced colitis.

The intricate interplay between the microbiome and host immunity unfolds through diverse mechanisms, including modulation of dendritic cells, T lymphocyte activation, and cytokine milieu shaping. Specific microbial taxa and their metabolic outputs influence these pathways, dictating pro-inflammatory or regulatory signals that may tip the balance toward immune tolerance or pathological inflammation. In the context of cancer immunotherapy, variations in the gut microbiome composition appear to not only influence therapeutic responses but also the incidence and severity of irAEs, suggesting that microbial ecology within the host is a critical determinant of treatment outcomes.

Clinical observations have substantiated correlations between distinct microbial profiles and the susceptibility to ICI colitis. Patients developing colitis frequently exhibit dysbiosis characterized by diminished representation of commensal bacteria known for their immunomodulatory capacity, such as members of the Ruminococcaceae and Bacteroidaceae families. Conversely, abundance of potentially pro-inflammatory organisms may predispose individuals to heightened immune activation within the intestinal mucosa, thus precipitating colitis. These microbial imbalances are hypothesized to disrupt mucosal barrier integrity, promote aberrant antigen presentation, and facilitate the infiltration of autoreactive lymphocytes.

Preclinical models mirror these clinical insights, demonstrating that germ-free or antibiotic-treated mice exhibit altered susceptibility to immune checkpoint blockade-induced colitis, further cementing the causal link between microbiota and irAEs. Fecal microbiota transplantation (FMT) from patients with favorable microbial composition has been shown to mitigate colitis in murine models, underscoring the therapeutic potential of microbiome modulation. Moreover, mechanistic studies highlight that specific microbial metabolites, such as short-chain fatty acids, can temper inflammatory cascades and promote regulatory T cell expansion, offering tangible molecular targets for intervention.

Adding layers to this complexity, longitudinal analyses reveal dynamic shifts in microbiome architecture coinciding with the initiation and progression of ICI therapy. These temporal changes suggest that therapeutic modulation of the microbiota—through diet, prebiotics, probiotics, or antibiotics—may represent viable strategies to preempt or ameliorate irAEs. However, the heterogeneity in patient microbial signatures and the multifactorial nature of irAE pathogenesis pose significant challenges to the delineation of universal predictive biomarkers or standardized interventions.

Beyond colitis, irAEs affecting the lungs (pneumonitis) and skin (dermatitis) also implicate resident microbiota in their etiopathology. The lung microbiome, though less dense than that of the gut, influences local immune tone and may contribute to pulmonary toxicity through similar immunomodulatory pathways. Similarly, cutaneous microbial communities interface with epidermal immune cells, shaping inflammatory responses that can escalate under immune checkpoint blockade, manifesting as diverse dermatologic adverse events.

The clinical ramifications of irAEs extend beyond immediate toxicity management; they can dictate the trajectory of cancer therapy, as severe events often necessitate immunosuppressive treatments that may paradoxically dampen anti-cancer immunity. Therefore, discerning strategies that selectively mitigate irAEs without compromising therapeutic efficacy is paramount. Emerging evidence posits the microbiome as a modifiable factor—one that can be harnessed to recalibrate immune responses, preserve the integrity of non-tumor tissues, and prolong the clinical benefits of ICIs.

Experimental therapeutic approaches targeting the microbiome are rapidly evolving. Fecal microbiota transplantation trials, selective antibiotic regimens, and designer probiotics are under investigation for their capacity to restore microbial balance and attenuate irAE severity. Concurrently, advances in multi-omics profiling enable high-resolution characterization of host-microbiome interactions, facilitating the identification of predictive signatures and informing personalized intervention protocols.

Fundamental questions remain, however, regarding the precise microbial constituents and metabolic pathways that govern irAE development, and how host genetics and environmental factors intersect with microbiome dynamics in this context. Elucidating these complex networks demands integrative research employing systems biology, immunology, and microbiology, synergized with robust clinical trial frameworks.

In summary, the evolving paradigm that implicates tissue microbiomes as critical arbiters in the genesis and modulation of immune-related adverse events marks a frontier in cancer immunotherapy research. Harnessing this knowledge heralds the advent of innovative therapeutic modalities that not only enhance patient safety but also sustain the revolutionary anticancer potential of immune checkpoint inhibitors. The journey from associative observations to mechanistic understanding and ultimately, clinical translation, holds the promise of transforming irAE management and optimizing immunotherapy outcomes on a global scale.

Subject to ongoing discovery and rigorous validation, the tapestry of host-microbiome interactions in immunotherapy toxicity underscores a quintessential example of precision medicine’s future, where microbiome-informed strategies tailor cancer care to individual immune landscapes. As research deepens, the microbiome might emerge as both a biomarker and a therapeutic target, redefining standards of care and profoundly influencing oncologic practice.

Subject of Research:
The role of microbiota in immune-related adverse events in cancer patients undergoing immune checkpoint inhibitor therapy, with a particular focus on gut microbiome involvement in immune checkpoint inhibitor-induced colitis.

Article Title:
Microbiota and immune-related adverse events in cancer immunotherapy

Article References:
Schneider, S.M., Fan, C., Wang, Y. et al. Microbiota and immune-related adverse events in cancer immunotherapy. Nat Rev Cancer (2026). https://doi.org/10.1038/s41568-026-00921-3

Image Credits: AI Generated

In a landmark study recently published in the Journal of Experimental Medicine, researchers from Cincinnati Children’s have delineated a molecular pathway responsible for immune checkpoint inhibitor-induced myocarditis, shedding light on how this devastating side effect may be prevented without compromising the cancer-fighting benefits of ICIs. The collaborative work, spearheaded by immunology expert Chandrashekhar Pasare, DVM, PhD, and cardiovascular biologist Jeffery Molkentin, PhD, along with first author Kathrynne Warrick, an MD-PhD candidate, introduces a paradigm-shifting approach to decouple anti-tumor activity from cardiac toxicity.

Immune checkpoint inhibitors act by disrupting inhibitory signals from checkpoint proteins, such as PD-1 and CTLA-4, that cancers exploit to camouflage themselves from T cell-mediated destruction. Since the FDA approval of Yervoy in 2011, ICIs have transformed once terminal diagnoses into manageable conditions by invigorating the immune response against malignancies. The Nobel Prize awarded to James Allison and Tasuku Honjo in 2018 underscored the monumental impact of checkpoint blockade immunotherapy.

Yet, despite these successes, approximately 2% of patients undergoing ICI therapy develop myocarditis, an autoimmune inflammation with alarmingly high mortality rates—approximately 50% succumb even when cancer is controlled. This cardiac side effect not only jeopardizes patient survival but also limits the wider applicability of ICIs. Understanding the cellular and molecular underpinnings of this complication has remained a critical unmet need.

To unravel the mechanisms of ICI-associated myocarditis, the Cincinnati Children’s team engineered an innovative mouse model replicating the human disease phenotype closely. Their systematic experimental approach unveiled that the myocarditis stems not from exhaustion of tumor-specific T cells, as previously speculated, but from the generation of autoreactive CD8+ T cells targeting cardiac myocytes. Crucially, the study identified tumor necrosis factor (TNF), a potent pro-inflammatory cytokine secreted by these autoreactive CD8+ T cells, as a pivotal mediator in initiating and sustaining the destructive cardiac inflammation.

The research underscores the critical role of TNF signaling through its receptor TNFR2 in cardiac myocytes to perpetuate myocarditis. Checkpoint inhibitor therapy inadvertently facilitates this signaling cascade, enabling autoreactive CD8+ T cells to recognize cardiac tissue epitopes as antigenic targets, leading to life-threatening cardiac arrhythmias. This insight offers a therapeutic target with immense potential.

Navigating from discovery to preclinical intervention, the researchers employed a selective TNF blockade strategy targeting TNFR2 in the murine model. Remarkably, this targeted inhibition arrested the inflammatory cascade responsible for myocarditis without diminishing the anti-tumor immune response. This selective blockade represents a groundbreaking approach, wherein the immune system is fine-tuned to spare cardiac tissues while retaining robust cancer cell eradication.

According to Dr. Molkentin, the ability to prevent arrhythmias and cardiac damage by intercepting TNF signaling in CD8+ T cells marks a significant advance with profound clinical implications. These findings lay the foundation for next-generation therapies that can be co-administered with ICIs to ameliorate immune-related adverse events (irAEs), essentially enabling cancer patients to benefit from immunotherapy with reduced risk of lethal cardiac inflammation.

However, translating these findings from mouse models to human patients demands further research. Questions regarding the safety profile and optimal treatment duration for TNFR2-specific TNF inhibitors need rigorous clinical evaluation. Currently, the development of TNFR2-selective antibodies remains in the experimental phase, underscoring the necessity for robust trials assessing their efficacy and toxicity in diverse patient populations undergoing checkpoint blockade immunotherapy.

Moreover, the study opens avenues to investigate whether similar immune mechanisms underlie irAEs affecting other vital organs during ICI treatments. If TNF-driven autoreactive T cell responses are also implicated in multisystem toxicities, targeted TNF inhibition could represent a universal strategy to enhance the safety of a broad spectrum of cancer immunotherapies.

The research team also acknowledges the extensive interdisciplinary collaboration and core facilities that enabled the project’s success. Contributions from veterinary services, flow cytometry, transgenic animal modeling, pathology research, and bio-imaging have all been instrumental in generating this impactful data. Funding support from the National Institutes of Health and the American Heart Association has been critical to advancing this innovative research.

As immune checkpoint inhibitors continue to alter the cancer treatment landscape worldwide, mitigating their serious adverse effects remains paramount. The elucidation of the TNF/TNFR2 axis as a mechanistic driver of myocarditis not only enhances our understanding of checkpoint inhibitor toxicity but also illuminates a promising translational path to safer, more effective cancer immunotherapy regimens. The integration of targeted immunomodulation with existing anticancer strategies offers hope for a future where life-extending checkpoint blockade therapies can be administered with minimal collateral damage to vital organs such as the heart.

Subject of Research: Animals

Article Title: Immune checkpoint inhibitor–induced myocarditis is dependent on CD8 T cell–derived TNF and TNFR2 signaling

News Publication Date: 20-Feb-2026

Web References: http://dx.doi.org/10.1084/jem.20251717

Image Credits: Cincinnati Children’s

Keywords: Health and medicine, Diseases and disorders, Cancer, Pharmaceuticals, Drug therapy, Drug safety

The research team meticulously analyzed cerebrospinal fluid obtained from patients before they commenced CAR-T therapy, leading to the discovery of several proteins that serve as biomarkers for predicting the development of ICANS. This research opens new avenues for enhancing patient safety, as early identification of high-risk individuals may allow for timely intervention or preventative measures that could mitigate the risk of severe neurological events.

The significance of this discovery cannot be overstated, especially given the increasing popularity of CAR-T-cell therapy, which has shown remarkable success in treating refractory blood cancers. However, patients undergoing this therapy are at risk of encountering serious and potentially fatal side effects, including inflammatory responses within the central nervous system that can lead to impaired consciousness, seizures, or even brain hemorrhages.

Dr. Yuya Kunisaki, a key figure in this study, emphasized the urgency of finding reliable predictive measures for ICANS, particularly considering the high incidence rate of this syndrome following CAR-T therapy—estimated to be around 64%. Kakuni, along with his colleagues, has identified specific proteins that exhibit distinct levels in patients who develop ICANS in comparison to those who do not, thereby positioning these proteins as viable biomarkers for the prediction of ICANS.

The researchers began their study with a sample of cerebrospinal fluid from 29 patients diagnosed with B-cell non-Hodgkin’s lymphoma. Through rigorous proteomic analysis, they identified a total of 864 different proteins present within the cerebrospinal fluid samples. Ultimately, their investigation narrowed this number down to 46 proteins that displayed significant differences in expression levels between patients who developed ICANS and those who remained unaffected.

Among these proteins, two emerged as particularly noteworthy: C1RL, which was found to be elevated in patients who developed ICANS, and FUCA2, which demonstrated decreased levels in the same group. By analyzing the ratio of these two proteins, the researchers established a predictive equation that achieved remarkably high accuracy, yielding a score of 0.95 in ROC curve analysis—an impressive validation of its predictive potential.

To confirm the efficacy of this predictive model, the researchers conducted a follow-up analysis with a second group of 10 patients undergoing CAR-T therapy. The results corroborated their earlier findings as the biomarker ratio accurately identified the risk of all patients for developing ICANS, thereby highlighting its robustness as a predictive tool.

Despite these promising findings, the researchers caution that their results are still preliminary due to the limited size of their sample population. As co-first author Dr. Tomoko Nomiyama pointed out, further studies with a larger cohort of patients are necessary to fully validate these observations and to strengthen the evidence for the biomarker ratios they have identified.

If subsequent studies confirm these preliminary results, the implications for clinical practice could be transformative. The identification of patients at high risk for ICANS through a simple cerebrospinal fluid analysis permits a paradigm shift in patient management—a proactive approach toward treatment that could include early interventions or preventive therapies aimed at reducing the likelihood of ICANS manifestations altogether.

Additionally, the researchers are exploring the feasibility of identifying similar predictive biomarkers in less invasive samples, such as blood serum. Given that the collection of cerebrospinal fluid is typically invasive and not routinely performed prior to CAR-T therapy in most hospitals, the ability to glean this vital information from standard blood tests would vastly improve accessibility and practicality for predicting ICANS.

This research not only underscores the potential for personalized medicine in the realm of cancer treatment but also exemplifies the promising intersection between proteomics and clinical oncology. By marrying advanced proteomic analysis with clinical insights, the ability to tailor cancer treatment to individual patient profiles is becoming increasingly realistic, paving the way for safer and more effective therapeutic strategies.

As the team continues to expand their research, they are committed to confirming the reliability of their biomarkers across a broader spectrum of blood cancers. The hope is that these findings could eventually lead to the establishment of universal predictive tests that could become standard practice in oncology settings, allowing for more informed treatment decisions and improved patient outcomes.

Ultimately, the strides made by this research team may redefine the landscape of cancer immunotherapy. With ongoing advancements in biomarker identification and validation, clinicians will be better equipped to preemptively address the risks associated with therapies like CAR-T-cell treatment, facilitating a more patient-centric approach to cancer care.

Subject of Research: People
Article Title: Cerebrospinal Fluid Proteomics Exerts Predictive Potential for ICANS in CAR-T Therapy
News Publication Date: 11-Mar-2025
Web References: Kyushu University
References: Nomiyama T., Setoyama D., Yamanaka I., et al. “Cerebrospinal Fluid Proteomics Exerts Predictive Potential for ICANS in CAR-T Therapy.” Leukemia.
Image Credits: Daiki Setoyama, Kyushu University

Keywords: ICANS, CAR-T therapy, cerebrospinal fluid, biomarkers, predictive model, proteomics, cancer immunotherapy, central nervous system, personalized medicine, Kyushu University.

A recently published case from the University Hospital of Cologne revealed a unique and alarming complication following CAR-T cell therapy. A 63-year-old patient diagnosed with multiple myeloma developed T cell lymphoma within just nine months after treatment. More disturbingly, the lymphoma emerged from the genetically modified T cells that were supposed to protect the patient, demonstrating not only the intricacies involved in such therapies but also the need for ongoing vigilance and research. This incident sheds light on the dual nature of engineered therapies: while they can be life-saving, they may also inadvertently give rise to new oncogenic processes.

The architects of this vital research collaboration, Professor Marco Herling and Dr. Till Braun, both renowned for their work in T cell lymphomas, aim to dissect the molecular mechanisms underpinning this phenomenon. They assert that while CAR-T therapies have shown promise, this particular case raises critical questions regarding the long-term safety and genetic integrity of the modified immune cells used in treatment. As Professor Maximilian Merz, the leading researcher on this study, notes, understanding the risks associated with CAR-T cell therapy could ultimately safeguard future patients from similar adverse reactions.

Through the employment of cutting-edge genomic technologies, researchers meticulously examined the genetic landscape of the patient’s cancer cells. They discovered that changes in the CAR-T cells alone did not account for the cancer’s emergence. Instead, pre-existing genetic alterations in the patient’s hematopoietic cells were also implicated, thus complicating our understanding of how patient-specific factors can modify treatment outcomes. This intricacy underlines the need for comprehensive genetic profiling as part of patient evaluation before proceeding with CAR-T cell therapy or similar immunological interventions.

Leveraging next-generation sequencing techniques, the research team performed whole-genome sequencing to unveil potential genetic alterations contributing to the lymphoma’s development. Furthermore, single-cell RNA sequencing afforded them the ability to delve into the transcriptomic landscape of the CAR-T cells, yielding insights into the gene expression profiles and signaling pathways at play within the malignant environment. These sophisticated methodologies not only provide clarity in this particular case but also serve as a blueprint for analyzing future cases of secondary malignancies arising from CAR-T treatments.

An integral facet of the study was the collaborative efforts between clinicians and basic scientists, particularly between the team at the University of Leipzig and the Fraunhofer Institute for Cell Therapy and Immunology (IZI). The synergy of clinical insight and laboratory expertise facilitated expedited analysis and interpretation of the findings. As one of Europe’s leaders in CAR-T cell therapies, the University of Leipzig serves as a pivotal node for pioneering advancements in the treatment of multiple myeloma and lymphomas, reinforcing the importance of interdisciplinary collaboration in biomedical research.

The implications of this study extend beyond individual case management; they also illuminate the broader risks associated with CAR-T therapies. As these innovative therapies become more accessible and prevalent, understanding the incidence and mechanisms of secondary tumors becomes increasingly critical. The research team is already planning further investigations to identify potential risk factors that could help predict and ultimately avert the occurrence of such side effects in future CAR-T treated patients.

In a response to their findings, the researchers have submitted a second manuscript summarizing this case as well as nine comparable instances from global literature to the esteemed journal "Leukemia." Rapid acceptance of their manuscript, occurring within just one day, underscores the significance of this work within the scientific community and exemplifies the urgency and relevance of acknowledging the risks involved with CAR-T cell therapy.

The rarity of these adverse events, noted as occurring in far less than one percent of cases, should not diminish the need for transparency regarding their existence and the mechanisms behind them. As outlined by Professor Herling, raising awareness while providing accurate data is essential to maintain the balance between advancing innovative treatments and ensuring patient safety. In an era where patient outcomes are prioritized, understanding complications becomes a crucial aspect of care that ultimately informs clinical practice and research.

To dissect the implications of such findings further, researchers are delving into the molecular and genetic profiles of these lymphomas. This will require an extensive collection of clinical data, genetic information, and treatment histories, with the ultimate aim of creating predictive models that could facilitate earlier interventions. As the knowledge surrounding CAR-T cell therapy continues to expand, so too must the mechanisms for monitoring and mitigating post-treatment complications.

As the field of immunotherapy burgeons, the dialogue between risk and reward must persist. Innovations in CAR-T therapy are promising, yet as cases like this demonstrate, meticulous monitoring and adaptive management strategies must be implemented to navigate the potential repercussions. Continuous research efforts, such as those driven by the EU project CERTAINTY, are vital to unraveling the complexities and nuances of CAR-T cell therapy outcomes.

Understanding the intricacies of T cell lymphomas that arise post-CAR-T therapy suggests a more complicated reality than initially conceived. This emphasizes the importance of not only advancing therapy techniques but also ensuring that we remain attuned to their potential long-term effects on patients. The hope is that with robust research frameworks and patient-centric approaches, the duality of immunotherapy can be harnessed effectively to provide life-saving outcomes without compromising patient safety.

Subject of Research: People
Article Title: Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody
News Publication Date: 21-Feb-2025
Web References: Link to manuscript
References: Not provided
Image Credits: Not provided
Keywords: CAR-T cell therapy, multiple myeloma, lymphoma, T cell lymphoma, genomic alterations, immunotherapy, genetic predispositions, adverse events, next-generation sequencing, interdisciplinary research.